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ABSTRACT-Of over 300 patients with erectile dysfunction, 186 were selected for intracavernosal 
autoinjection therapy with a standardized papaverine-phentolamine mixture. A total of 156 pa- 
tients performed 4,813 protocol autoinjections with a minimum of 10 and a maximum of 230 per 
patient. The dose that induced a full erection at the hospital could be reduced under home condi- 
tions by a mean of 35 per cent. Systemic side effects were not observed. The most inconvenient local 
side effects were prolonged erections in 24 patients in diagnostic use and In 3 patients in therapeutic 
use. These were treated easily without further consequences. 
In 1974, Klinge and Sjostrand,’ from Scandi- 
navia, examined the effects of various neuro- 
transmitters and vasoactive drugs on the mus- 
culus retractor penis and the arteria penis of the 
bull. Virag2 reported in 1982 on the periodic in- 
tracavernosal application of papaverine in 
man, that restored erectile potency in 4114 pa- 
tients. One year later, Brindley3 described the 
demand-oriented intracavernosal injection of 
the alpha-receptor-blockade, phenoxyben- 
TABLE I. Exclusion criteria for diagnostic 
and therapeutic use of intracavernous 
injection of vasoactive drugs 
Age over 65 years 
Cardiac dysrhythmias 
AOD Stages III and IV 
Addiction 
Severe liver or kidney disease 
Sexual deviation 
Duration of erectile dysfunction less 
than one year 
Unreliable and noncooperative 
Datient 
zamine. In 1984, Zorgniotti and Lefleul”’ intro- 
duced autoinjection therapy with a vasoactive 
drug combination for erectile dysfunction. 
Meanwhile, intracavernosal injection of va- 
soactive drugs has found widespread use in 
diagnosis and therapy of erectile dysfunction. 68 
Long-term experience with this therapy is lack- 
ing, but side effects of other application forms, 
such as severe liver changes after i.v. pa- 
paverine, call for close observation of possible 
local or systemic side effects. 
Material and Methods 
Between February, 1985, and January, 1987, 
over 300 patients with erectile dysfunction last- 
ing over one year underwent multidisciplinary 
examinations at our hospital to elucidate the 
origin of their erectile failure. Since vasoactive 
substances were to be used for diagnosis, pa- 
tients with arterio-occlusion (AOD) (Stages III 
and IV), cardiac dysrhythmias, severe liver or 
kidney diseases, or patients older than sixty-five 
years were excluded because adverse reactions 
were anticipated (Table I). 
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TABLE II. Acceptance of autoinjection therapy 
-Per Cent of- 
Acceptance Patients Partners 
Very good 42.7 41.2 
Good 26.0 29.8 
Satisfied 23.8 25.2 
Less satisfied 6.0 3.8 








The following tests were performed: anam- 
nesis with the aid of a questionnaire, physical 
examination, blood tests (fats, testosterone, and 
prolactin), sexual anamnesis and psychometry 
(MMPI), b u lb ocavernosus reflex (BCR), soma- 
tosensory evoked potential (SSEP) of the dorsal 
nerve of the penis, ultrasonography of the large 
vessels, Doppler ultrasound study of the penile 
arteries, and penile brachial pressure index 
(PBI). Selective penile angiography was per- 
formed on 59 patients and dynamic cavernosog- 




Subsequently, intracavernosal standardized 
pharmacotesting was done. After informed 
consent was obtained, each patient received an 
injection of papaverine hydrochloride 7.5 mg 
and phentolamine mesylate 0.25 mg into the 
proximal right corpus cavernosum by means of 
a 26-G needle. This dose was reduced or 
doubled the following day(s), depending on the 
rigidity obtained, until a full erection was in- 
duced (max. 45 mg papaverine + 1.5 mg phen- 
tolamine). This standardized pharmacotesting 
proved to be helpful in the differential diagnosis 
of vascular penile disturbances.e 
B I 2 
I m h 
4 6 
FIGURE 1. (A and B) Intmcavernosal blood gas 
analysis ajter two hours (n = 4), four hours (n = 4), 
and six hours (n = 4) of jull erection induced by 
vasoactive drugs. 
Of these patients, 186 were carefully selected 
for intracavernosal autoinjection therapy at 
home. Patients with sexual deviation or addic- 
tion were excluded. The levels of reliability and 
cooperation of the patients were very impor- 
tant. The dose was adapted to induce an erec- 
tion of thirty to sixty minutes under hospital 
conditions. The patients were advised to reduce 
this dose, if the duration of full erection ex- 
ceeded ninety minutes at home. The patients 
were reviewed after 10 and then all 25 autoin- 
jections. Blood chemistry and ultrasound study 
of the penis were performed after all 50 injec- 
tions. In case of a prolonged erection (after 4 
hours), they were advised to return to the hospi- 
tal immediately. 
Results 
In a follow-up period of from three to 
twenty-four months, 156 patients performed 
4,813 protocol autoinjections with a minimum 
of 10 autoinjections per patient. A total of 52 of 
156 patients performed more than 35 injec- 
tions, 21 of 156 more than 100, and 7 of 156 
more than 200 injections at home. Fourteen pa- 
tients reported a significant improvement in 
spontaneous erections with full erections up to 
fourteen days after the injection. Six patients 
regained spontaneous erections within the 
first 10 injections (4 psychogenic, 2 mild arte- 
rial). Ten patients abandoned this therapy 
(Table 11). The patients reduced the individu- 
ally adapted dose in hospital under home condi- 
tions by a mean of 35 per cent (1.27 mL to 0.89 
mL). No patient reported systemic side effects. 
In 40 consecutive patients, continuous moni- 
toring of pulse and blood pressure showed no 
influence on these cardiovascular parameters 
after the intracorporeal injection. No signifi- 
cant changes in blood chemistry were observed. 
In 3 patients with 35 to 60 autoinjections, a lo- 
calized (< 5 mm) thickening of the tunica albu- 
ginea occurred. After eight weeks of noninjec- 
tion, the thickening resolved in 3 of 3 patients. 
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No cavernous fibrosis was detectable by palpa- 
tion or ultrasound examinations. 
In diagnostic use, 26 prolonged erections 
(pharmacologically induced erection) occurred 
in 24 patients. Because they involve the risk of 
ischemic damage to the cavernous tissue with 
resulting irreversible erectile impotence,‘O pro- 
longed erections should be stopped after a max- 
imum of six hours (Fig. 1). The first 4 patients 
were treated by puncture and aspiration, the 
others by administration of 2.5 mg or 2 mg of 
metaraminol intracavernosally. 
During autoinjection therapy, 3 prolonged 
erections occurred within the first 1,000 appli- 
cations. In each case, the patient had injected 
another dose after he had thought the first to be 
unsuccessful. Intracavernosal injections of 2.5 
mg metaraminol into the right and 1 mg into 
the left corpus cavernosa led to complete flac- 
cidity. Ever since we warned our patients not to 
administer more than 1 injection per day, no 
prolonged erections during home treatments 
were reported. In none of the patients were fi- 
brotic changes of the corporeal tissue, 
cavernitis, penile deviation, or anaphylactoid 
reaction observed. Intradermal hematomas (2- 
5 mm) occurred with 2 to 3 per cent of the in- 
jections and were resorbed without conse- 
quences. 
Comment 
The most inconvenient short-term side effect 
of therapy with intracavernosal vasoactive 
drugs is prolonged erections. Various authors re- 
port a frequency of about 5 to 10 per cent in 
diagnostic use. 5-8~10 Therefore, the patient 
should be in close contact with the urologist, es- 
pecially at the beginning of therapy, and pro- 
longed erections must be interrupted after a 
maximum of six hours. 
Systemic side effects on the cardiovascular 
system were absent objectively and subjectively 
in our patients. This is probably due to the 
small doses we administer (mean 19.05 mg pa- 
paverine + 0.64 g phentolamine). Other 
authors who reported occasional systemic side 
effects such as dizziness, inject up to 160 mg 
papaverine. 5,11 
No cavernous fibrosis due to autoinjection 
therapy, as reported by other authors,12J3 was 
seen in our patients, even in those with more 
than 200 injections. Our drug mixture has a pH 
4.5 whereas papaverine hydrochloride has a pH 
2.7. Further follow-up is necessary to reveal the 
incidence of intracavernosal fibrosis in our pa- 
tients. 
In our opinion, the requirements for diagno- 
sis and therapy of erectile dysfunction with va- 
soactive drugs are (1) the preselection and 
cooperation of the patient, (2) a physiologically 
adapted mixture, and (3) a urologist expe- 
rienced in treating side effects. 
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